Harmony Biosciences is a commercial-stage pharmaceutical company founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania. The company focuses on developing and commercializing innovative therapies for patients with rare neurological diseases. It conducted an initial public offering on NASDAQ in 2020.
The company's first commercial product received FDA approval in 2019 for rare neurological diseases. Its approach is built on a patient-focused drug development model that incorporates patient insights to inform clinical research. The organization is guided by core principles of empathy and innovation.
Harmony Biosciences has been recognized as a Great Place to Work for eight consecutive years and was named a Fortune Best Workplace in BioPharma. The company operates within the pharmaceutical, neurology, and rare disease industry verticals.
